Drugs / SYH9017
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06830343 | Feb 2025 → Aug 2026 overdue | obesity disorder | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH9017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06830343 ↗ |
| Route | Subcutaneous | “Subjects in SAD experimental groups will receive a single subcutaneous injection of SYH9017 on Day 1” NCT06830343 ↗ |